Special Drug Use-Results Survey of OPDIVO (classical Hodgkin's lymphoma)

Special Drug Use-Results Survey of OPDIVO (all case surveillance) [relapsed or refractory classical Hodgkin's lymphoma]

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080224013

Enrollment

250

Registered

2018-07-26

Start date

2016-12-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

classical Hodgkin's lymphoma

Interventions

investigational material(s) Generic name etc : Opdivo Intravenous Infusion 20 mg, Opdivo Intravenous Infusion 100 mg INN of investigational material : nivolumab Therapeutic category code : 429 Other a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with relapsed or refractory classical Hodgkin's lymphoma to whom OPDIVO was administered

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
safety Safety items : Occurrence status of adverse events (including adverse drug reactions)	—

Secondary

Measure	Time frame
efficacy Efficacy items : Comprehensive improvement (the best antitumor efficacy by 6 and 12 months after the initiation of OPDIVO or by the end or discontinuation of the treatment)	—

Countries

Japan

Contacts

Public ContactTakafumi Nakao

Ono Pharmaceutical Co.,LTD

pms_contact_ml@ono-pharma.com+81-662225501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026